Published in J Hyg (Lond) on October 01, 1974
Use of pulsed-field gel electrophoresis for epidemiological study of Bordetella pertussis in a whooping cough outbreak. J Clin Microbiol (1994) 4.13
Identification of a 69-kilodalton nonfimbrial protein as an agglutinogen of Bordetella pertussis. Infect Immun (1988) 2.55
Prevalent serotypes of Bordetella pertussis in non-vaccinated communities. J Hyg (Lond) (1976) 1.57
Conversion of Bordetella pertussis to Bordetella parapertussis. J Hyg (Lond) (1978) 1.32
Mouse or man? Which are pertussis vaccines to protect? J Hyg (Lond) (1976) 1.28
A reappraisal of serotype factors 4, 5 and 6 of Bordetella pertussis. J Hyg (Lond) (1982) 1.11
The stability of the serotypes of Bordetella pertussis with particular reference to serotype 1,2,3,4. J Hyg (Lond) (1976) 1.09
Bordetella pertussis serotypes in Canada. Can Med Assoc J (1978) 0.88
Serological studies on H. pertussis H. parapertussis and H. bronchisepticus. Acta Pathol Microbiol Scand (1953) 7.00
Antigenic modulation of Bordetella pertussis. J Hyg (Lond) (1960) 4.61
Technical problems in the laboratory diagnosis and prevention of whooping-cough. Lab Pract (1970) 3.05
Potency tests for pertussis vaccines: doubtful value of intracerebral challenge test in mice. J Pathol Bacteriol (1966) 2.73
Efficacy of pertussis vaccines: a brighter horizon. Br Med J (1972) 2.04
Variation in Bordetella pertussis. J Pathol Bacteriol (1967) 1.36
Experimental pertussis infection in the marmoset: type specificity of active immunity. J Hyg (Lond) (1974) 1.31
Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet (2001) 3.24
Technical problems in the laboratory diagnosis and prevention of whooping-cough. Lab Pract (1970) 3.05
Potency tests for pertussis vaccines: doubtful value of intracerebral challenge test in mice. J Pathol Bacteriol (1966) 2.73
Toxoid vaccine for pertussis. Lancet (1997) 2.43
Efficacy of pertussis vaccines: a brighter horizon. Br Med J (1972) 2.04
Protection by pertussis vaccine. Little cause for concern. Lancet (1976) 1.63
Change in serotype of pertussis infection in Britain. Lancet (1985) 1.60
Prevalent serotypes of Bordetella pertussis in non-vaccinated communities. J Hyg (Lond) (1976) 1.57
Agglutinin response to pertussis vaccination in the child. Br Med J (1971) 1.51
Measles control in young infants. Lancet (1993) 1.45
Polio eradication. Lancet (1994) 1.40
Experimental pertussis infection in the marmoset: type specificity of active immunity. J Hyg (Lond) (1974) 1.31
Identification of Vibrio cholerae by pyrolysis gas-liquid chromatography. Appl Microbiol (1973) 1.30
Diphtheria carriers in Manchester: simultaneous infection with toxigenic and non-toxigenic mitis strains. Lancet (1980) 1.29
Mouse or man? Which are pertussis vaccines to protect? J Hyg (Lond) (1976) 1.28
Whooping-cough in Hertfordshire. Lancet (1979) 1.27
Letter: Whooping-cough vaccination. Lancet (1974) 1.19
Some unsolved problems with vaccines. Prog Drug Res (1979) 1.12
A reappraisal of serotype factors 4, 5 and 6 of Bordetella pertussis. J Hyg (Lond) (1982) 1.11
Pneumonectomy for drug resistant mycobacterium malmoense. Thorax (1983) 1.11
Cholera vaccines: lessons from Rwanda and elsewhere. Lancet (1997) 1.10
Whooping cough in northern Israel. Isr J Med Sci (1972) 1.08
Fluconazole in the treatment of candidal prosthetic valve endocarditis. BMJ (1988) 1.07
Identification of airborne dissemination of epidemic multiresistant strains of Pseudomonas aeruginosa at a CF centre during a cross infection outbreak. Thorax (2003) 1.06
Essential immunogens in human pertussis: the role of fimbriae. Dev Biol Stand (1985) 1.02
Experimental pertussis infection in the rabbit: similarities with infection in primates. J Infect (1980) 1.01
Some factors affecting the haemolytic activity of Vibrio cholerae. J Med Microbiol (1974) 0.99
Pertussis agglutinins in vaccinated children: better response with adjuvant. J Hyg (Lond) (1974) 0.98
Recognising whooping cough. Br Med J (Clin Res Ed) (1986) 0.98
Accelerated immunisation with diphtheria-tetanus-pertussis vaccine. BMJ (1991) 0.98
Machakos project studies. Agents affecting health of mother and child in a rural area of Kenya. V. Pertussis sentypes in Kenyan children 1974--1975. Trop Geogr Med (1978) 0.95
Application of pulsed field gel electrophoresis to the 1993 epidemic of whooping cough in the UK. Epidemiol Infect (1995) 0.94
Pertussis agglutinins in vaccinated mice : difficulty in estimating the type-specific response. Indian J Med Res (1976) 0.91
A clinical trial using co-trimoxazole in an attempt to reduce wound infection rates in dog bite wounds. Postgrad Med J (1985) 0.90
Histamine-sensitising factor of Bordetella pertussis differentiated from immunogens by neutralisation and passive protection tests. J Pathol Bacteriol (1967) 0.90
Whooping cough in West Germany. Lancet (1985) 0.88
Netilmicin prophylaxis in open-heart surgery. J Antimicrob Chemother (1984) 0.88
Burkholderia gladioli: recurrent abscesses in a patient with cystic fibrosis. J Infect (2001) 0.85
Toxicity of pertussis vaccine. Br Med J (Clin Res Ed) (1982) 0.83
What makes a good pertussis vaccine? Prog Drug Res (1975) 0.82
Comparison of once daily trimethoprim and standard co-trimoxazole in urinary infections. A clinical trial in general practice. Practitioner (1982) 0.82
Efficacy of whooping-cough vaccines. Br Med J (1973) 0.82
Aspergillus niger endocarditis complicating aortic tissue valve replacement. Thorax (1984) 0.81
Vaccine composition in relation to antigenic variation of the microbe: is pertussis unique? Prog Drug Res (1975) 0.80
Characterization of outbreak and vaccine strains of Bordetella pertussis--Quebec. Can Commun Dis Rep (1993) 0.80
Electron microscopy and serological features of a patient with Q fever prosthetic valve endocarditis. J Clin Pathol (1996) 0.79
Current pharmacotherapy of pertussis. Expert Opin Pharmacother (2001) 0.79
Inhaled corticosteroid aerosols and candidiasis. Br J Dis Chest (1979) 0.78
Type-specific action of vibriocidal antibody on Vibrio cholerae. J Hyg (Lond) (1975) 0.78
Pertussis component vaccine in Japan. Lancet (1984) 0.78
Association between Bordetella pertussis agglutinogen 2 and fimbriae. J Med Microbiol (1984) 0.77
Pulmonary pertussis infection in the mouse: no solution to an old problem. J Infect (1981) 0.76
Transmission of pertussis: do adults have an important role? Lancet (1996) 0.76
Acellular pertussis vaccines: progress but déjà vu. Lancet (1998) 0.75
Diphtheria, pertussis, and tetanus vaccination. Lancet (1992) 0.75
Assessing the response to pertussis vaccine. BMJ (1991) 0.75
Immunological and bacteriological distinction between parapertussis and pertussis. Lancet (1995) 0.75
Changing advice on vaccination. Br Med J (1979) 0.75
Measles and pertussis: the timing of vaccination. Lancet (1995) 0.75
Components of acellular pertussis vaccines. Lancet (1996) 0.75
Aneurysm of the mitral valve complicating Streptococcus milleri endocarditis. Postgrad Med J (1983) 0.75
Publication bias via suppressed expert conflict. Lancet (1993) 0.75
Cholera isolates in relation to the "eighth pandemic". Lancet (1993) 0.75
Cholera treatment. Lancet (1994) 0.75
Letter: Immunisation against whooping cough. Br Med J (1976) 0.75
Immunisation of the preterm baby. J Infect (1994) 0.75
Centenary of the Gram-stain. J Infect (1984) 0.75
Whooping cough in Stuttgart. Lancet (1988) 0.75
Pertussis antibodies in vaccinated children. Lancet (1983) 0.75
Eradication of pertussis by vaccination. Lancet (1987) 0.75
Typhoid vaccine and laboratory indicators of clinical protection. Lancet (1992) 0.75
Experimental pertussis infection in the vaccinated and unvaccinated marmoset: similarities to natural infection in the child. J Clin Pathol (1972) 0.75
The motility of some clostridium species. J Gen Microbiol (1969) 0.75
Antigens that modern vaccines must contain. Lancet (1990) 0.75
Promiscuity and the abuse of stigma. Lancet (2000) 0.75
Whooping-cough immunization: fact and fiction. Public Health (1980) 0.75
Influence of challenge strain on potency of pertussis vaccines in mice. Nature (1967) 0.75
Vibrio cholerae in South America. Lancet (1984) 0.75
Whooping-cough vaccine. Lancet (1977) 0.75
Actinomycosis of the tongue. J Infect (1991) 0.75
Whooping cough vaccine efficacy. Lancet (1982) 0.75
Campylobacter serotypes and epidemiology. Lancet (1981) 0.75
Whooping-cough vaccination. Br Med J (1979) 0.75
Vaccination and the eradication of infectious diseases. Natl Med J India (1998) 0.75
Maternal antibody against pertussis. Br Med J (1977) 0.75
Pertussis vaccine efficacy in Birmingham. Commun Dis Public Health (2000) 0.75
Bacterial septicaemia with multiple organisms complicating influenzal pneumonia. Br Med J (1977) 0.75